Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Yap1 inhibitors that target the interaction of yap1 with oct4

A C1-C8, C1-C6 technology, applied in medical preparations containing active ingredients, drug combinations, organic chemistry, etc., can solve problems such as low overall survival rate

Inactive Publication Date: 2019-06-04
H LEE MOFFITT CANCER CENT & RES INST INC
View PDF15 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although chemotherapeutic agents such as gemcitabine, platinum compounds, and taxanes have improved survival to a limited extent, overall survival remains poor due to recurrence of more aggressive, drug-resistant tumors (Seve P et al. Chemoresistance in small cell lung cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Yap1 inhibitors that target the interaction of yap1 with oct4
  • Yap1 inhibitors that target the interaction of yap1 with oct4
  • Yap1 inhibitors that target the interaction of yap1 with oct4

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0215] The following examples are listed below to illustrate the methods and results according to the disclosed subject matter. These examples are not intended to cover all aspects of the subject matter disclosed herein, but to illustrate representative methods and results. These embodiments are not intended to exclude the equivalents and variations of the present invention, which are obvious to those skilled in the art.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Binding of the transcriptional co-activator, YAP1, to the transcription factor Oct4, induces Sox2, which is a transcription actor necessary for the self-renewal of stem-like cells from non-small celllung cancer. The WW domain of YAP1 binds to the PPxY motif of Oct4 to induce Sox2. Delivering a peptide corresponding to the WW domain could prevent the induction of Sox2 and stemness. Similarly, peptides and mimetics of the PPxY motif would be able to inhibit stemness. Disclosed are compounds that affect the Yap1:Oct4 interaction.

Description

[0001] Cross references to related applications [0002] This application claims the priority rights of U.S. Provisional Application 62 / 396,190 filed on September 18, 2016 and U.S. Provisional Application 62 / 396,383 filed on September 19, 2016. The entire contents of these two provisional applications are incorporated by reference. Into this article. Background technique [0003] Lung cancer is the leading cause of cancer-related mortality in the United States (Siegel R et al., Cancer Statistics, 2013. CACancer J Clin. 2013; 63(1): 11-30), of which most (85%) are caused by non-small Caused by cell lung cancer (NSCLC). Surgery is used to treat patients with early disease, but about 30-60% of them will develop recurrent tumors that lead to death (Demicheli R et al., the recurrence dynamics do not depend on the recurrence site. Breast Cancer Res. 2008; 10(5): R83; Demicheli R Et al. The recurrence dynamics of non-small cell lung cancer: the impact of surgery on the development of me...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D401/06C07D403/06A61K31/454A61K31/496
CPCC07D401/06A61K45/06C07D401/12C07D405/06C07D413/12C07D207/16C07D211/34C07D211/58C07D211/96A61P35/00C07C255/57C07C271/24C07C237/14C07C237/22C07C251/24C07C2601/14C07D211/32C07D403/06C07D241/04C07D211/14C07D211/56C07D233/64C07D263/32C07D257/04C07D233/92A61K31/454A61K31/496C07D211/60C07D401/10C07D405/12
Inventor 斯里库玛·希尔拉潘尼古拉斯·J·劳伦斯苏吉瓦·拉纳通加·马汉泽·穆迪扬塞拉格
Owner H LEE MOFFITT CANCER CENT & RES INST INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com